CDC review examines SARS-CoV-2 rebound in COVID-19 patients with and without antiviral treatment

The Centers for Disease Control and Prevention (CDC) conducted a review of studies examining SARS-CoV-2 rebound in patients with COVID-19. The review compared patients who received antiviral treatment to those who did not. The main outcome of interest was the occurrence of SARS-CoV-2 rebound, but the review did not report specific effect sizes, absolute case numbers, p-values, confidence intervals, or the direction of any observed association.

No safety or tolerability data regarding adverse events, serious adverse events, or treatment discontinuations were reported in the available summary. The review's methodology, including the specific number of studies analyzed, the patient sample size, study settings, and follow-up duration, was not detailed.

Key limitations stem from the lack of reported quantitative data and study design specifics. The review's findings are descriptive, and without comparative metrics, the strength of any observed association between antiviral use and viral rebound cannot be assessed. The practice relevance is constrained; this review highlights an area for surveillance but does not provide evidence to alter current antiviral prescribing practices for COVID-19.